African Medicines Agency Strengthens Regulatory Framework to Protect Patients and Boost Local Pharma

The African Medicines Agency (AMA) has marked a significant milestone in strengthening regulatory systems to protect patients and boost local pharmaceutical manufacturing. The World Health Organisation (WHO) has confirmed that ten African national regulatory authorities have attained Maturity Level 3 under its Global Benchmarking Tool. This achievement represents progress towards more reliable medicines oversight and stronger cross-border cooperation. The ten countries that have achieved this milestone include Egypt, Ethiopia, Ghana, Mozambique, Nigeria, Rwanda, Senegal, South Africa, Tanzania, and Zimbabwe.

A Maturity Level 3 rating describes a stable, well-functioning, and integrated regulatory system. The benchmarking framework assesses essential functions such as product registration and marketing authorisation, market surveillance, regulatory inspections, laboratory testing, pharmacovigilance, and clinical-trial oversight. However, maturity assessments are tied to specific product categories and regulatory scopes, and should not be interpreted as a blanket guarantee covering every medical product or regulatory function in a country. This achievement is an important institutional milestone, but it remains distinct from the WHO Listed Authority designation, which involves a separate assessment of advanced regulatory performance.

The practical value of stronger regulatory systems extends beyond national borders. Medicines and pharmaceutical ingredients move through international supply chains, meaning weaknesses in one market can create risks elsewhere. Greater cooperation allows authorities to exchange safety information, coordinate inspections, and rely on assessments conducted by trusted regulators. This can reduce duplication while helping countries maintain appropriate standards for the quality, safety, and efficacy of medical products. For manufacturers, more aligned regulatory procedures can also reduce the time and cost of seeking product authorisation across multiple markets.

The African pharmaceutical market is valued at tens of billions of dollars, with more than 70% of pharmaceuticals consumed on the continent being imported. Regulation is therefore also an industrial policy tool. Local pharmaceutical production cannot expand sustainably without predictable requirements for licensing, quality assurance, inspections, and product approval. The objective is not to weaken oversight in the interest of industrial growth, but to develop regulatory systems that protect patients while enabling compliant manufacturers to invest, improve production, and compete across regional markets.

The AMA's structural challenge, however, remains participation. As of October 2026, only 33 of the African Union's 55 member states had ratified the AMA Treaty, leaving 22 yet to join the framework. The agency's ability to advance regulatory harmonisation across the continent will depend partly on broader participation and the willingness of member states to cooperate in practice. The Kigali meeting sought to strengthen this institutional foundation, with the inauguration of seven AMA technical committees covering areas including medicines and vaccines evaluation, clinical-trial oversight, inspections, vigilance, and medical devices.

The event also saw the launch of the Regulatory Innovation and Manufacturing Readiness Hub and the Capacity Strengthening Hub, intended to provide technical support, strengthen regulatory expertise, and encourage local pharmaceutical manufacturing. These initiatives build on the framework agreement between WHO and AMA signed in May 2026, alongside a five-year joint operational plan. Their effectiveness will depend on sustained political and financial support, capable national institutions, and practical cooperation among participating countries.

An ML3 rating is an institutional benchmark, not a measure of whether medicines are affordable or available in clinics. Governments should therefore monitor indicators such as review times, inspection coverage, safety-alert response, and essential-medicine availability alongside regulatory maturity. The broader lesson from AMA Week is that patient protection, regional cooperation, and industrial development are interconnected priorities. Stronger regulatory institutions can help African countries improve public health safeguards while creating a more predictable environment for pharmaceutical investment.

Key points

• The African Medicines Agency has marked a significant milestone in strengthening regulatory systems to protect patients and boost local pharmaceutical manufacturing.
• Ten African national regulatory authorities have attained Maturity Level 3 under the WHO's Global Benchmarking Tool.
• The AMA's structural challenge remains participation, with only 33 of the African Union's 55 member states having ratified the AMA Treaty.